• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
Gynesonics

Gynesonics

Advancing technology. Improving women's lives.

  • Our Company
    • About Us
    • Careers
    • Compliance and Quality
  • Our People
    • Management
    • Board of Directors
    • Investors
  • Our Technology
    • The Sonata System
    • Indications and Safety
    • Instructions for Use
    • Request for Medical or Scientific Information
  • Our News
    • Press Releases
    • In the News
    • Publications
  • Contact Us

bsmith

Gynesonics Announces New Category 1 CPT Code for its Sonata Transcervical RF Ablation Procedure Used to Treat Uterine Fibroids

January 3, 2024

REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Gynesonics®, Inc. a privately-held women’s healthcare medical device company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that with the support of the American College of

Gynesonics to announce completion of latest funding round soon, new CEO says

October 31, 2023

Originally published by Mergermarket 25 Oct 2023 17:55 EDT Gynesonics, a Redwood City, California-based women’s healthcare and medical device company, plans to announce the completion of a significant financing round soon, said new CEO Skip Baldino. The company announced a USD 25m financing

Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids Reaches Patient Milestones in the U.S. and Globally

October 17, 2023

REDWOOD CITY, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, is pleased to announce that its Sonata® Procedure has been used to treat over 1,000 women in the United

SSM Medical Minute on Fox 2 News Talks Uterine Fibroid Treatment with Sonata TFA

September 19, 2023

Dr. Brigid Holleran-Schwartz of SSM Health, talks with Fox 2 News in St. Louis, MO. about the Sonata Treatment. The Sonata Treatment is an incisionless solution clinically proven to reduce fibroid symptoms including heavy menstrual bleeding. This treatment can address a wide range of fibroid types

Stony Brook Medicine’s Patient Shares How Sonata Improved Her Quality of Life

September 11, 2023

Donna Febo, a patient of Stony Brook Medicine in New York, thought her heavy bleeding and pelvic pain were caused by her body approaching menopause. After talking with Dr. Conway, they were able to identify two fibroids to be the likely culprits causing her symptoms. Dr. Conway suggested the Sonata

Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids is Now Covered by UnitedHealthcare

August 11, 2023

REDWOOD CITY, CA, August 1, 2023 – Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, is pleased to announce that its Sonata® Procedure is now covered by UnitedHealthcare, effective August 1, 2023. 

Novant Health highlights Sonata TFA technology that destroys fibroids and preserves normal uterine tissue

August 1, 2023

The Sonata System is an effective method of treating uterine fibroids using radiofrequency ablation (RFA). Sonata is an incisionless procedure that uses a handpiece with a radiofrequency tip that targets and treats fibroids from within the uterus while preserving healthy uterine tissue. Read

Holland Hospital Talks About the Sonata Treatment with WoodTV for Fibroid Awareness Month

July 17, 2023

July is Fibroid Awareness Month. Fibroids are non-cancerous tumors that grow in and around the uterus and have the potential to cause a variety of symptoms including heavy menstrual bleeding. To spread awareness relief from symptomatic fibroids, Dr. Jim Gerard, an OB-GYN at Holland Hospital, spoke

  • Page 1
  • Page 2
  • Page 3
  • Next Page »

Primary Sidebar

  • Privacy Notice
  • Cookie Notice
  • Terms of Use
  • Impressum
  • Patents
  • Safety Information

© Copyright 2025 Gynesonics · All Rights Reserved · WS 05198 Rev. L

  • Privacy Notice
  • Cookie Notice
  • Terms of Use
  • Impressum
  • Patents
  • Safety Information